Browse by author
Lookup NU author(s): Professor Matthew CollinORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2020 Informa UK Limited, trading as Taylor & Francis Group. In contrast to Fms-like tyrosine kinase 3 (FLT3), the influence of FLT3 ligand (FLT3L) on acute myeloid leukemia (AML) biology and disease prognosis has been poorly described. Here we provide an overview of the role played by FLT3L in AML. While being a cytokine implicated in the regulation of hematopoiesis, both in normal situation and after intensive chemotherapy, FLT3L has also a role in enhancing proliferation, inhibiting apoptosis and conferring resistance to FLT3 inhibitors in AML. Moreover, recent independent data show how its measurement may be helpful in the disease management. Indeed, FLT3L could provide a low cost, rapid and noninvasive assessment of chemosensitivity and blast clearance that has robust prognostic significance for patients with AML.
Author(s): Peterlin P, Chevallier P, Knapper S, Collin M
Publication type: Review
Publication status: Published
Journal: Leukemia and Lymphoma
Online publication date: 20/10/2020
Acceptance date: 03/10/2020
ISSN (print): 1042-8194
ISSN (electronic): 1029-2403
Publisher: Taylor and Francis Ltd.